Nurix Therapeutics (NRIX)
Develops protein-degradation medicines through DEL-AI and large-pharma collaborations.
Something off on this page? Send us feedback.
Develops targeted protein degradation medicines for cancer, inflammatory disease, and other indications through DEL-AI. Revenue is collaboration-based rather than product-based, with Roche, Gilead, Sanofi, and Pfizer shaping the pipeline and funding model.
Develops targeted protein degradation therapies through DEL-AI, a discovery platform built around E3 ligases and small-molecule modulation of cellular proteins. The main clinical programs are bexobrutideg, zelebrudomide, and NX-1607, alongside partnered IRAK4, STAT6, and DAC programs.
Operations are concentrated in Brisbane, California, with a research-heavy employee base and outsourced clinical trial and manufacturing work. Bexobrutideg moved into pivotal development for relapsed or refractory CLL and is now co-developed with Roche across malignant hematology, immunology, and neurology.
The business has no approved product revenue in the context reviewed. Collaboration economics with Roche, Gilead, Sanofi, and Pfizer, clinical trial outcomes, manufacturing partners, and competition from protein degradation and other therapeutic modalities shape the operating model.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $36 | Target: $38 |
| Jul 22, 2026 | UBS | Reiterate | Rating: —Target: $23 | Target: $31 |
| Jul 13, 2026 | Mizuho Securities | Target | Target: — | Target: $34 |
| Jul 10, 2026 | RBC Capital | Reiterate | Rating: —Target: $29 | Target: $33 |
| Jul 10, 2026 | Truist Financial | Target | Target: $32 | Target: $34 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, May 31, 2026Cash & short-term investments $443.5M · Total debt $58.1M · Total assets $535.5M · Shareholders' equity $402.6M
- Revenue
- $9.0M
- Operating income
- −$94.2M
- Net income
- −$89.5M
No dividends on record.
| Institutions | ≈ 113.36% | 117.65M shares | |
|---|---|---|---|
| 218 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.17% | 177.3K shares | |
| 4 holders · as of Sep 2, 2026 | |||
| Adds to | 113.53% | ||
103.78M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 113.53%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.45% | 8.77M | as of Jun 30, 2026 |
Vestal Point Capital, LPInstitution | 7.76% | 8.05M | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 7.45% | 7.74M | as of Jun 30, 2026 |
Rubric Capital Management LPInstitution | 6.96% | 7.23M | as of Jun 30, 2026 |
FMR LLCInstitution | 5.29% | 5.49M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Christine Ring | officer: Chief Legal Officer | −5,787 | $25.76 |
| Sep 1, 2026 | Gwenn Hansen | officer: Chief Scientific Officer | −1,452 | $25.47 |
| Aug 4, 2026 | Gwenn Hansen | officer: Chief Scientific Officer | −4,111 | $24.36 |
| Aug 5, 2026 | Gwenn Hansen | officer: Chief Scientific Officer | −4,356 | $25.00 |
| Aug 4, 2026 | Hans van Houte | officer: Chief Financial Officer | −4,761 | $24.36 |
- BeOne Medicines (ADR)
BTK inhibitor and degrader pressure in B-cell malignancies
- Eli Lilly
Non-covalent BTK inhibitor pressure in relapsed CLL/SLL
- AstraZeneca (ADR)
Covalent BTK inhibitor standard in CLL/SLL and MCL
- Kymera Therapeutics
Oral degrader platform overlap in STAT6 and IRAK4 biology
- Arvinas
PROTAC platform peer with the first FDA-approved degrader
- AbbVie
Ibrutinib franchise and BTK-degrader pipeline overlap
- Monte Rosa Therapeutics
Molecular glue degrader peer in immunology and oncology
- C4 Therapeutics
Oncology TPD peer with IKZF1/3 and DAC programs
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nurix Therapeutics | $25.65 | +0.94% | $2.64B | — | — | 71.7 | −79.5% |
| BeOne Medicines (ADR) | $364.07 | −0.44% | $39.07B | 5.1 | 46.1 | 6.4 | +29.6% |
| Eli Lilly | $1,168.84 | +0.34% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| AstraZeneca (ADR) | $168.47 | +0.22% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Kymera Therapeutics | $121.11 | +2.92% | $9.68B | — | — | 92.2 | +466.4% |
| Arvinas | $8.45 | +1.81% | $535.5M | 51.9 | — | 1.7 | +1,014.7% |
| AbbVie | $265.35 | +0.33% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Monte Rosa Therapeutics | $12.29 | +0.24% | $1.04B | — | — | 36.1 | −61.2% |
| C4 Therapeutics | $3.34 | +1.21% | $364.9M | — | — | 10.4 | +2.8% |
| Median | 39.1 | 23.0 | 8.8 | +19.9% |